Insider · CIK 0001859810
Sandra Milligan
Files at AWHL (Aspira Women's Health Inc.), SYRE (Spyre Therapeutics, Inc.), GOSS (Gossamer Bio, Inc.). First filing Aug 20, 2025, latest Aug 20, 2025.
Sandra Milligan files SEC Form 4 as president, CEO and director at GOSS (Gossamer Bio, Inc.), and also at AWHL (Aspira Women's Health Inc.), SYRE (Spyre Therapeutics, Inc.). Since Aug 20, 2025, Sandra Milligan has reported 1 open-market buy worth $50k and 0 open-market sells worth $0, the latest filed on Aug 20, 2025.
A track record needs three past buys with six months of prices behind them; Sandra Milligan has 0, so none is measured yet.
The newest scored trade: bought $50k of GOSS on Aug 19, 2025, filed Aug 20, 2025, scored 32 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GOSS: Gossamer Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | 18 d ago |
| Jun 4, 2026 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 5, 2026 |
| Aug 19, 2025 | GOSS Gossamer Bio, Inc. | POpen-market purchase Common Stock | +26,050 | $1.92 | $50k | 58,050 | Aug 20, 2025 |
| Jun 25, 2025 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 26, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| Dec 31, 2024 | AWHL Aspira Women's Health Inc. | MOption exercise Common Stock | +20,000 | $0.00 | $0 | 20,000 | Jan 8, 2025 |
| Dec 31, 2024 | AWHL Aspira Women's Health Inc. | MOption exercise Restricted Stock Unitsderivative | -20,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Nov 12, 2024 | AWHL Aspira Women's Health Inc. | AGrant or award Stock option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Nov 13, 2024 |
| Oct 28, 2024 | AWHL Aspira Women's Health Inc. | AGrant or award Restricted Stock Unitsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 28, 2024 |
Questions about Sandra Milligan
Answered from the filings on this page, as of the latest one.
Is Sandra Milligan buying or selling?
Not in the last 12 months. Sandra Milligan's latest open-market trade on SEC Form 4 was bought $50k of GOSS on Aug 19, 2025.
How did Sandra Milligan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandra Milligan has 0.
Where does Sandra Milligan file Form 4?
Sandra Milligan has filed Form 4 at GOSS (Gossamer Bio, Inc.); AWHL (Aspira Women's Health Inc.) as Interim CEO & President; SYRE (Spyre Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.